Ardelyx (ARDX) Financial Analysis & Valuation | Quarter Chart

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for... more
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to tre... more

Company facts

Reported company information and share structure.

Company Share structure
Market Cap$1.28BExchangeNASDAQ
SectorHealthcareIndustryBiotechnology
CountryUSCEOMichael G. Raab
IPO Date2014-06-19CAGR39.43%
Employees489Websitewww.ardelyx.com
Div. Yield—Payout Ratio—
Buy Back Yield—Total Yield—
ARDX chart loading...

Key metrics

Reported fundamentals and market-derived technical indicators.

Fundamentals Technicals
Enterprise Value$1.40BP/E Ratio-24.3
Forward P/E10.1PEG Ratio—
P/S Ratio0.24P/B Ratio0.69
P/CF Ratio-2.79P/FCF Ratio-2.71
EPS$-0.21EPS Growth 1Y—
EPS Growth 3Y—EPS Growth 5Y—
Revenue Growth 1Y18.24%Gross Margin0.92%
Operating Margin-0.09%Profit Margin-0.14%
ROE-0.38%ROA-0.12%
ROCE-0.09%Current Ratio3.49
Quick Ratio3.28Cash Ratio0.28
Debt/Equity1.4Interest Coverage-1.29
Altman Z Score0.7Piotroski Score2

View Ardelyx financial charts →

Ardelyx (ARDX) valuation & financials

Ardelyx (ARDX) has a market capitalization of $1.28B and trades at a price-to-earnings ratio of -24.3. It operates in the Healthcare sector (Biotechnology).

Ardelyx's revenue grew +18.2% over the last year.

Ardelyx's next earnings report is scheduled for August 3, 2026 after market close; analysts estimate EPS of $-0.05.

📈 Analysts estimate ARDX EPS of $-0.05 for the upcoming quarter. See Ardelyx revenue & EPS analyst forecasts for the next four quarters with Quarter Chart Premium.

Ardelyx (ARDX) — frequently asked questions

When does Ardelyx (ARDX) report earnings next?

Ardelyx is expected to report earnings on August 3, 2026 after market close. Analysts estimate EPS of $-0.05.

What is Ardelyx's market cap?

Ardelyx (ARDX) has a market capitalization of $1.28B.

What is ARDX's P/E ratio?

Ardelyx trades at a price-to-earnings ratio of -24.3, with trailing twelve-month EPS of $-0.21.

How fast is Ardelyx growing?

Ardelyx's revenue grew +18.2% over the last year.

Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Roche (ROG.SW) · Merck (MRK)

Ardelyx revenue & earnings charts →